Formation Of Proprietary Company
Monte Rosa Therapeutics is a biotechnology company developing molecular glues to degrade disease-causing proteins. The company has created a platform to rationally design small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable.
For more information, visit www.
BayCoast Bank is pleased to announce that June D. Goguen has been promoted to Senior Vice President and Commercial.
For partnerships, content marketing or advertising inquiries, please contact Edwin through his LinkedIn Profile. Contribute Advertise Promote.
Navigation menu
Sign up for: Email Newsletter. A particular focus is on ubiquitin E3 ligases, their role in protein degradation and ways in which these enzymes can be reprogrammed by small molecules. Michael Rape, Ph. His team studies enzymes that control cell division and differentiation, two processes often misregulated in cancer. Ian Collins, Ph.
Sponsor Center
In particular, Professor Collins has a strong interest in using protein structures to understand how drugs bind to their target proteins and how to improve their properties. Eliezer Van Allen, M. Kimberly Blackwell, M. Prior to joining Tempus, she was vice president of early-phase Ckmpany and immuno-oncology at Eli Lilly.
David Schenkein, M.
Schenkein co-leads the life science investment team.]
It agree, it is a remarkable phrase